Barclays analyst Gena Wang lowered the firm’s price target on Vir Biotechnology (VIR) to $26 from $28 and keeps an Overweight rating on the shares post the Q3 report. The firm expects multiple data updates to provide near-term upside, with “strong balance sheet supporting long-term growth.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- U.S. drugmakers shifting away from Chinese supply-chain partners, WSJ says
- Vir Biotechnology Reports Q3 2024 Financial Results
- Vir Biotechnology reports Q3 EPS ($1.56), consensus ($1.05)
- JMP Securities healthcare analysts hold an analyst/industry conference call
- Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments